Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It is one of the most aggressive solid malignancies. The late diagnosis, therapy resistance, and enormous molecular heterogeneity can explain the high mortality rate of PDAC. Besides the characteristic driver mutations in the KRAS, CDKN2A, SMAD4, and TP53 genes, epigenetic mechanisms also foster the aggressiveness of PDAC. The enhancer of zeste homolog 2 (EZH2) is an epigenetic regulator often found overexpressed in PDAC. Both canonical and non-canonical functions of EZH2 are believed to contribute to its aggressive oncogenic activity. Hence, MS1943, a selective EZH2 degrader, has been developed and has proven therapeutic efficacy in breast cancer. This study aims to characterize the effects of MS1943 in various PDAC cell lines to assess the consequences of EZH2 degradation on EZH2-dependent target gene regulation and its functional impact on PDAC progression. Optimal MS1943 dose and time kinetics were determined in various PDAC cell lines by analyzing EZH2 protein levels. The functional implications of MS1943 on cell viability, proliferation, stemness, migration, senescence, and apoptosis were assessed by MTT-, image-based determination of cell confluency-, colony formation-, wound healing-, ß Galactosidase-, and Annexin V/PI apoptosis assays, respectively. Phenotypic changes upon EZH2 degradation were compared to functional consequences following specific inhibition of the EZH2 methyltransferase activity (Tazemetostat). Furthermore, the effects of MS1943 treatment on the transcriptome were analyzed by mRNA-sequencing in primary patient-derived PDAC cells. A subset of identified EZH2 target genes regulated by MS1943 was selected for independent validation studies in a panel of PDAC cells. Experiments in our study demonstrate that MS1943 reduces proliferation, viability, migration, and colony formation in all tested PDAC cell lines. However, PDAC cells differ in their sensitivity to MS1943, with variations observed in both the effective concentration and their functional consequences. In contrast, Tazemetostat treatment did not cause any of these effects, thus hinting towards the implications of non-canonical EZH2 functions in PDAC. Transcriptomic analysis via mRNA-sequencing revealed an enrichment of senescence- and apoptosis-related gene signatures upon MS1943 administration. Consistently, EZH2 degradation fostered senescence and apoptosis of PDAC cells. Moreover, further experiments demonstrated that MS1943 enhances the VI Abstract efficacy of chemotherapeutic agents. However, a reduction in cell growth and metabolic activity upon MS1943 treatment was also observed in PDAC cells with EZH2-knockout, which leads to the suggestion that MS1943 may engage cellular targets on top of the EZH2 degradation, which might contribute to the observed phenotypic alterations. Our findings suggest that MS1943 holds promise as a therapeutic agent for PDAC by targeting its oncogenic activities. However, further investigations are required to understand the mechanisms and to assess potential off-target effects of MS1943 on PDAC cells.